Results 1 to 10 of about 5,148 (157)

An in-depth investigation of NAs-induced osteoporosis adverse events: a real-world, network toxicology and molecular docking analysis [PDF]

Frontiers in Medicine
BackgroundNucleoside and nucleotide analogs are one of the mainstays of treatment for chronic hepatitis B, but their effects on bone density are highly controversial.MethodsIn this study, four pharmacovigilance analysis methods and Bonferroni-corrected p-
Jingkai Di, Jingkai Di, Shuang Wang, Lujia Liu, Likun Qi, Zijian Guo, Yingda Qin, Chuan Xiang   +7 more
doaj   +2 more sources

Adefovir anticancer potential: Network pharmacology, anti-proliferative & apoptotic effects in HeLa cells [PDF]

Biomolecules & Biomedicine
Cervical cancer presents a significant healthcare challenge due to recurrent disease and drug resistance, highlighting the urgent need for novel therapeutic strategies.
Muzammal Mateen Azhar, Tahir Maqbool, Fatima Ali, Awais Altaf, Muhammad Atif, Zulfiqar Ali, Zahid Habib Qureshi, Muhammad Naveed, Tariq Aziz, Rania Ali El Hadi Mohamed, Fakhria A. Al-Joufi, Maher S. Alwethaynani   +11 more
doaj   +2 more sources

Evaluation of Adefovir PBPK Model to Assess Biomarker‐Informed OAT1 Drug–Drug Interaction and Effect of Chronic Kidney Disease [PDF]

CPT: Pharmacometrics & Systems Pharmacology
Evaluation of transporter‐mediated drug–drug interactions (DDI) with endogenous biomarkers, coupled with physiologically‐based pharmacokinetic modeling (PBPK) is envisioned to replace or reduce dedicated DDI clinical trials with clinical probe substrates.
Shawn Pei Feng Tan, Huaying Wu, Amin Rostami‐Hodjegan, Daniel Scotcher, Aleksandra Galetin   +4 more
doaj   +2 more sources

Adefovir dipivoxil-induced hypophosphatemic osteomalacia and osteoporosis: a case report and literature review [PDF]

Frontiers in Endocrinology
The nephrotoxicity of adefovir dipivoxil (ADV) can induce Fanconi syndrome, which causes hypophosphatemic osteomalacia. We report a case of a 67-year-old postmenopausal woman who had been receiving long-term adefovir dipivoxil therapy for chronic ...
Wenshu Yu, Chunxia Deng, Shangyu Chen, Hui Jiang, Jiaqin Jiang   +4 more
doaj   +2 more sources

Overcoming Immunotolerance in Chronic Hepatitis B: Efficacy of Granulocyte‐Macrophage Colony‐Stimulating Factor–Based Immunotherapy in Achieving Hepatitis B Surface Antigen Seroclearance [PDF]

MedComm, Volume 7, Issue 4, April 2026.
Chronic hepatitis B patient (CHB) presents a challenge due to immune tolerance toward HBV surface antigen (HBsAg). This study aimed to achieve a functional cure by disrupting HBV tolerance through immunotherapy. CHB received standard NA therapy, or NA combined with IFN‐α, while a third group received the THRIL‐GM‐Vac regimen.
Shuang Geng, Feifei Yang, Hongyu Jia, Gan Zhao, Weidong Zhao, Jie Yu, Haoxiang Zhu, Huan Cai, Lishan Yang, Shuren Zhang, Fang Yu, Xiang Jin, Shijie Zhang, Xianzheng Wang, Yida Yang, Jiming Zhang, Bin Wang   +16 more
wiley   +2 more sources

Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response [PDF]

Clinical and Molecular Hepatology, 2020
Background/Aims Suboptimal responses to lamivudine or telbivudine plus adefovir (LAM/LdT+ADV) rescue therapy are common in patients with LAM-resistant hepatitis B virus (HBV) infections. We compared patients switched to entecavir plus tenofovir (ETV+TDF)
Hyun Young Woo, Jun Yong Park, Si Hyun Bae, Chang Wook Kim, Jae Young Jang, Won Young Tak, Dong Joon Kim, In Hee Kim, Jeong Heo, Sang Hoon Ahn   +9 more
doaj   +1 more source

The Elegance of the Acyclic Nucleoside Phosphonates (ANPs), Honorary Tribute to Antonín Holý, Who Passed Away on 16 July 2012, at the 10th Anniversary of His Death

Viruses, 2022
My collaboration with Prof. Antonín Holý, that spans a period of 3–4 decades (1976–2012), led to the discovery of several acyclic nucleoside phosphonates (ANPs) which were clinically developed by Gilead Sciences: cidofovir, adefovir, and tenofovir.
Erik De Clercq
doaj   +1 more source

Adefovir for lamivudine-resistant hepatitis B

Antiviral Therapy, 2022
Adefovir, a nucleotide analog developed by John Martin, was a major breakthrough in the treatment of chronic Hepatitis B. Prior to adefovir, Hepatitis B treatment was limited to two therapeutic modalities, either interferon, which carried significant ...
Rebecca Roediger, Elizabeth Kula Smyth, Douglas Dieterich   +2 more
doaj   +1 more source

Adverse Events During Pregnancy Associated With Entecavir and Adefovir: New Insights From a Real-World Analysis of Cases Reported to FDA Adverse Event Reporting System

Frontiers in Pharmacology, 2022
Background: Due to the embryotoxicity found in animal studies and scarce clinical data in pregnant women, it is still controversial whether entecavir (ETV) and adefovir dipivoxil (ADV) are safe during human pregnancy. This is of paramount importance when
Renjun Yang, Renjun Yang, Nuoya Yin, Nuoya Yin, Ying Zhao, Dandan Li, Xuanling Zhang, Xingang Li, Yang Zhang, Yang Zhang, Francesco Faiola, Francesco Faiola   +11 more
doaj   +1 more source

Evaluation of Ion-pair Formation of Adefovir to Improve Permeation across Artificial and Biological Membranes

Journal of Pharmacy & Pharmaceutical Sciences, 2018
Purpose: Adefovir is an antiviral drug that exhibits high hydrophilic properties and negligible bioavailability (less than 12%). It is only applied in the form of the ester prodrug adefovir dipivoxil (ADV). The oral bioavailability of ADV is limited (32%
Bahar Darsazan, Alireza Shafaati, Afshin Zarghi, Seyed Alireza Mortazavi   +3 more
doaj   +1 more source